Navigation Links
Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
Date:5/16/2008

REINACH, Switzerland, May 16 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for intravenous iclaprim in the treatment of complicated Skin and Skin Structure Infections (cSSSI). Arpida completed the submission of the NDA to the agency in March 2008. FDA has assigned a standard ten month review to the iclaprim NDA and has established the Prescription Drug User Fee Act (PDUFA) action date for the NDA to be 16 January 2009.

Dr Jurgen Raths, CEO of Arpida Ltd. commented: "We are very pleased with the FDA's acceptance of our NDA. This marks another step towards our goal of launching iclaprim and providing a promising treatment option for patients suffering from serious or life-threatening infections. We look forward to continue to work with the US authorities to facilitate their review of the NDA. In the meantime, work on the European filing is progressing and we expect to submit the Marketing Authorisation Application in the EU around the middle of this year. Furthermore, we will increasingly focus on the build-up of a commercial structure."

The iclaprim NDA contains data from 15 clinical studies, including two well-controlled multinational pivotal Phase III trials (ASSIST-1 and ASSIST-2, in which approximately 1,000 patients were enrolled and treated). Patients enrolled in both Phase III trials exhibited high incidences of methicillin-resistant Staphylococcus aureus (MRSA). In these studies, iclaprim showed high clinical and microbiological cure rates and was well-tolerated with a safety profile which was compatible with treatment of patients with cSSSI.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The mo
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... announces that a new market research report ... Neurostimulation - A Global Market Perspective ... world neurostimulation market stands enthused by the ... resultant rise in age-related diseases such as, ...
(Date:12/2/2009)... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... and dosimetry trial of Cotara® in patients with relapsed ... Cotara is a targeted monoclonal antibody linked to ... for GBM. Cotara specifically targets cells at the ...
(Date:12/2/2009)... Cell announced today,a feasibility study evaluating the preclinical ... product which combines technology from Weill,Cornell Medical College ... to,treat inherited anemias such as Cooley,s Anemia. , ... a series of technologies to expand, ex vivo,populations ...
(Date:12/2/2009)... going through,extraordinary times; markets are in turmoil and uncertainty ... that the pharma industry has been,relatively immune to the ... During the midst of the difficult ... an R&D center in Shanghai, the largest of,its kind ...
Breaking Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
... 5 Genta,Incorporated (OTC Bulletin Board: GNTA) announced today ... institutional and accredited,investors to place Senior Secured Convertible ... million in gross proceeds before fees and expenses. ... is expected to take place on or,about June ...
... Pa., June 5 ViroPharma Incorporated,(Nasdaq: VPHM ) notes ... its,Advisory Committee for Pharmaceutical Science and Clinical Pharmacology to,be held ... at this,meeting, including a discussion of:, " ... ... bioequivalence methods for locally acting drugs that treat ...
... Research Associates, LLC,announced today that it has issued ... (AAH: ASX). The full 56-page report can,be found ... Ltd. ("Arana" or "the Company") is a biotechnology,company ... cancer. Arana,s business is divided into two,sectors: (1) ...
Other Biology Technology:Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 2Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 3Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 4Viropharma Comments On Upcoming FDA Advisory Committee Meeting 2Viropharma Comments On Upcoming FDA Advisory Committee Meeting 3Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd. 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd. 3
(Date:12/4/2009)... This release is available in German . ... Biology of Ageing could help to understand the positive effect ... organisms (fruit flies and mice) have shown that dietary restriction ... diminished fertility. So the female fruit fly reproduces less frequently ...
(Date:12/3/2009)... co-workers discovered that specific types of human papillomavirus (HPV) ... pathogens cause cells to degenerate. It is known today ... E7. Both proteins switch off different cellular control functions, ... Rsl and his co-workers at DKFZ have now discovered ...
(Date:12/3/2009)... message: , , Preliminary Press Conference Topics, ... of Sciences museum, Attention PIOs: Sending Press Releases ... deadline 10 December, News Media registration information , ... 7 December, Who,s coming, , For important ...
Breaking Biology News(10 mins):How nutrition affects healthy aging 2Papillomavirus silences innate immune response 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Video 3A National Minority Quality Forum Launches First U S HIV AIDS Atlas 49648 1Video 3A National Minority Quality Forum Launches First U S HIV AIDS Atlas 49648 2Video 3A National Minority Quality Forum Launches First U S HIV AIDS Atlas 49648 3MapHIV org Shows Massachusetts Suffolk County Seriously Impacted by HIV and AIDS 49645 1MapHIV org Shows Massachusetts Suffolk County Seriously Impacted by HIV and AIDS 49645 2MapHIV org Shows Massachusetts Suffolk County Seriously Impacted by HIV and AIDS 49645 3MapHIV org Shows 18 25 of Georgias Counties are Seriously Impacted by HIV 49642 1MapHIV org Shows 18 25 of Georgias Counties are Seriously Impacted by HIV 49642 2MapHIV org Shows 18 25 of Georgias Counties are Seriously Impacted by HIV 49642 3
... University of Malaya (UM) today announced the establishment of ... is the first Centre of its kind in improving ... in terms of their diet and disease, conducting research ... and health, providing assistance for the national cancer registry ...
... Observatory of Singapore (EOS) which aspires to be ... several of civilisation,s most serious environmental threats ... aims to provide invaluable research and data, ... potentially save hundreds of thousands of lives. ...
... ocean bubbles up naturally from the seafloor, with Earth giving ... NASA satellites collect thousands of images and 1.5 terrabytes of ... because no one thinks there is a use for it. ... an otherwise undistinguished mass of ocean imagery. Chuanmin Hu, an ...
Other Biology News:Queen's University Belfast improves Malaysian public health 2The Earth Observatory of Singapore devoted to the study of earth sciences officially opens 2The Earth Observatory of Singapore devoted to the study of earth sciences officially opens 3Scientists find black gold amidst overlooked data 2Scientists find black gold amidst overlooked data 3
Human peripheral blood PBMCs, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Umbilical cord blood mononuclear cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Biology Products: